Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients

Clinical Transplantation

Volumn 19, Issue 3, 2005, Pages 340-345

  Morris, Jon A ^a   Hanson, J E ^a   Steffen, B J ^a   Chu, A H ^a   Chi Burris, K S ^a   Gotz, V P ^a   Gordon, R D ^b  

^a ProSanos Corporation   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

Daclizumab; Induction; Renal; Transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; DACLIZUMAB; GLYCOSAMINOGLYCAN POLYSULFATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CONTROLLED STUDY; DATA BASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HOSPITAL DISCHARGE; HUMAN; KAPLAN MEIER METHOD; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; REGISTER; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK REDUCTION; SHORT COURSE THERAPY; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; SURGICAL MORTALITY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 19044364387     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2005.00344.x     Document Type: Article

References (11)

1. Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998: 338: 161.
2. Vincenti F, Nashan B, Light S. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. Transplant Proc 1998: 30: 2155.
3. Ahsan N, Holman MJ, Jarowenko MV, Razzaque MS, Yang HC. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am J Transplant 2002: 2: 568.
4. Wiland AM, Philosophe B. Daclizumab induction in solid organ transplantation. Expert Opin Biol Ther 2004: 4: 729.
5. Vincenti F, Pace D, Birnbaum J, Lantz M. Pharmocokinetic and pharmocodynamic studies of one or two doses of daclibumab in renal transplantation. Am J Transplant 2003: 3: 50.
6. Fellstrom B. Cyclosporine nephrotoxicity. Transplant Proc 2004: 36(2 Suppl.): 220S.
7. Vincenti F. The role of newer monoclonal antibodies in renal transplantation. Transplant Proc 2001: 33: 1000.
8. Fangmann J, Arns W, Marti H et al. Impact of daclizumab and low dose cyclosporine in combination with mycophenolate mofetil and steroids on renal function after kidney transplantation. Am J Transplant 2004: 4 (Suppl. 8): 353 (Abstract #715).
9. Ekberg H, Persson NH, Kallen R, Gul-Baykurt N. Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenlate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation. Scand J Immunol 2003: 58: 670.
10. Meier-Kriesche HU, Schold J, Titte R, Srinivas T, Womer K, Hemming A, Kaplan B. Long term risks of antibody induction therapy in kidney transplantation. Am J Transplant 2004: 4(Suppl. 8): 264 (Abstract #386).
11. Braun WE. Renal transplantation: basic concepts and evolution of therapy. J Clin Apheresis 2003: 18: 141.